Daily Endocrinology Research Analysis
Three impactful endocrinology papers advanced mechanistic and translational understanding: a Nature Genetics single-cell atlas maps the DNA methylome and 3D genome of human subcutaneous adipose tissue and links obesity GWAS risk to specific cell types; a JCI study shows that incretin receptor agonists rapidly inhibit AgRP neurons to suppress feeding, clarifying GLP-1/GIP neural mechanisms; and a Diabetes Care analysis of 19-year DPP/DPPOS data identifies metabolic trajectory subgroups that diffe
Summary
Three impactful endocrinology papers advanced mechanistic and translational understanding: a Nature Genetics single-cell atlas maps the DNA methylome and 3D genome of human subcutaneous adipose tissue and links obesity GWAS risk to specific cell types; a JCI study shows that incretin receptor agonists rapidly inhibit AgRP neurons to suppress feeding, clarifying GLP-1/GIP neural mechanisms; and a Diabetes Care analysis of 19-year DPP/DPPOS data identifies metabolic trajectory subgroups that differentially predict micro- and macrovascular complications and define prevention windows.
Research Themes
- Adipose tissue epigenomics and 3D genome in obesity
- Neuroendocrine mechanisms of incretin-mediated appetite suppression
- Precision risk stratification across the prediabetes-to-diabetes continuum
Selected Articles
1. Single-cell DNA methylome and 3D genome atlas of human subcutaneous adipose tissue.
Using single-nucleus methyl-3C sequencing, the study maps cell type–resolved DNA methylation and 3D chromatin architecture in human subcutaneous fat. Adipocytes show hypomethylation and dense short-range 3D contacts linked to adipogenesis, and their regulatory regions are enriched for abdominal-obesity GWAS variants, connecting genetic risk to specific adipose cell programs.
Impact: This atlas provides foundational mechanistic insight by linking obesity genetics to specific adipose cell types and 3D regulatory architecture, enabling hypothesis-driven target discovery in metabolic disease.
Clinical Implications: While preclinical, mapping adipose cell–type regulatory landscapes and GWAS enrichment can prioritize targets for obesity and insulin resistance and guide cell type–specific interventions (e.g., adipocyte vs myeloid pathways).
Key Findings
- Adipocytes and adipose progenitors are hypomethylated whereas myeloid cells are hypermethylated, accounting for nearly half of 705,063 DMRs.
- Adipocytes exhibit enriched short-range chromatin interactions and complex local 3D structures associated with adipogenesis.
- Adipocyte DMRs and A compartments are enriched for abdominal obesity GWAS variants and polygenic risk; myeloid A compartments are enriched for inflammation.
- TET1 and DNMT3A are implicated as regulators shaping cell type–specific methylation profiles.
Methodological Strengths
- Single-nucleus combined methylome and 3D genome (snm3C-seq) enabling cell type–resolved multi-omic mapping.
- Integration with GWAS to functionally anchor genetic signals to cellular regulatory architecture.
Limitations
- Cross-sectional tissue sampling limits causal inference on dynamic remodeling.
- Restricted to subcutaneous adipose tissue; visceral adipose and other depots were not profiled.
Future Directions: Extend profiling to visceral fat and disease states, perturb TET1/DNMT3A and 3D contacts to test causality, and functionally validate GWAS-prioritized regulatory elements in adipocyte subtypes.
The cell-type-level epigenomic landscape of human subcutaneous adipose tissue (SAT) is not well characterized. Here, we elucidate the epigenomic landscape across SAT cell types using snm3C-seq. We find that SAT CG methylation (mCG) displays pronounced hypermethylation in myeloid cells and hypomethylation in adipocytes and adipose stem and progenitor cells, driving nearly half of the 705,063 differentially methylated regions (DMRs). Moreover, TET1 and DNMT3A are identified as plausible regulators of the cell-type-level mCG profiles. Both global mCG profiles and chromosomal compartmentalization reflect SAT cell-type lineage. Notably, adipocytes display more short-range chromosomal interactions, forming complex local 3D genomic structures that regulate transcriptional functions, including adipogenesis. Furthermore, adipocyte DMRs and A compartments are enriched for abdominal obesity genome-wide association study (GWAS) variants and polygenic risk, while myeloid A compartments are enriched for inflammation. Together, we characterize the SAT single-cell-level epigenomic landscape and link GWAS variants and partitioned polygenic risk of abdominal obesity and inflammation to the SAT epigenome.
2. Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice.
In vivo neural recordings demonstrate that endogenous GIP is necessary for nutrient-driven inhibition of AgRP neurons, while pharmacologic GLP-1 and GIP agonists both suppress AgRP activity. Dual GIP/GLP-1 agonism produces greater AgRP inhibition and anorexia, linking neural circuit effects to clinical efficacy of modern incretin therapies.
Impact: It clarifies gut–brain mechanisms by which incretin therapies suppress appetite and explains why dual GIP/GLP-1 agonists outperform single agents, informing next-generation anti-obesity drug design.
Clinical Implications: Supports the central role of AgRP neuron inhibition in incretin-induced anorexia and provides a mechanistic basis for developing targeted incretin therapies that maximize efficacy with improved tolerability.
Key Findings
- Endogenous GIP, but not GLP-1, is required for physiologic nutrient-mediated inhibition of AgRP neurons.
- Pharmacologic GIP and GLP-1 analogs rapidly inhibit AgRP neurons; the degree of inhibition correlates with reduction in food intake.
- Dual GLP-1/GIP receptor agonism more potently suppresses AgRP activity and feeding than either agonist alone.
Methodological Strengths
- In vivo fiber photometry directly links hormone action to real-time AgRP neuron activity.
- Comparative interrogation of endogenous physiology versus pharmacologic agonism, including dual agonist effects.
Limitations
- Mouse models may not fully capture human central mechanisms or side effect profiles.
- Short-term neural and behavioral readouts; chronic adaptations were not assessed.
Future Directions: Test causal necessity/sufficiency of AgRP neuron inhibition for incretin-induced anorexia, map receptor expression and downstream circuits, and evaluate chronic effects and translatability in higher species.
The incretin receptor agonists semaglutide and tirzepatide have transformed the medical management of obesity. The neural mechanisms by which incretin analogs regulate appetite remain incompletely understood, and dissecting this process is critical for the development of next-generation antiobesity drugs that are more targeted and tolerable. Moreover, the physiologic functions of incretins in appetite regulation and gut-brain communication have remained elusive. Using in vivo fiber photometry, we discovered distinct pharmacologic and physiologic roles for the incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). We showed that GIP, but not GLP-1, was required for normal nutrient-mediated inhibition of hunger-promoting AgRP neurons. By contrast, both GIP and GLP-1 analogs at pharmacologic doses were sufficient to inhibit AgRP neurons. The magnitude of neural inhibition was proportional to the effect of each incretin on food intake, and dual GIP and GLP-1 receptor agonism more potently inhibited AgRP neurons and suppressed food intake than either agonist alone. Our results have revealed a role for endogenous GIP in gut-brain appetite regulation and indicate that incretin analogs act in part via AgRP neurons to mediate their anorectic effects.
3. Longitudinal Metabolic Trajectories in Diabetes Prevention Program Participants Reveal Subgroups With Varying Micro- and Macrovascular Complication Risks.
Across 19 years of DPP/DPPOS, tensor decomposition uncovered four metabolic trajectories starting in prediabetes. An insulin-resistant trajectory (12%) predicted high microvascular complications, while a renal-dysfunction trajectory (15%) with early microalbuminuria doubled cardiovascular events, often before diabetes onset—defining earlier prevention windows.
Impact: It operationalizes precision prevention by linking long-term metabolic patterns from prediabetes to specific complication risks and highlights microalbuminuria as a pre-diabetes marker for macrovascular prevention.
Clinical Implications: Screening for microalbuminuria and trajectory-informed risk can prioritize early cardiovascular prevention before diabetes onset; insulin-resistant trajectories warrant intensified microvascular surveillance and targeted lifestyle/pharmacologic interventions.
Key Findings
- Four longitudinal clusters from prediabetes were identified using tensor decomposition and mixture modeling.
- An insulin-resistant trajectory (12%) had 92% progression to T2D and markedly higher retinopathy (OR 8.8) and neuropathy (OR 3.4).
- A renal-dysfunction trajectory (15%) with baseline microalbuminuria doubled cardiovascular events (HR 2.0) and showed progressive eGFR decline, often before T2D onset.
- Two clusters (73%) remained metabolically stable with low cumulative micro- and macrovascular events despite substantial T2D incidence.
Methodological Strengths
- Large, well-characterized cohort with 19-year follow-up starting in prediabetes.
- Advanced longitudinal analytics (tensor decomposition, Gaussian mixtures) with outcome validation via Cox/logistic models.
Limitations
- Observational clustering limits causal inference and may be sensitive to modeling choices.
- External validation in independent cohorts and implementation pathways are needed.
Future Directions: Prospective validation of trajectories, testing tailored interventions for renal-dysfunction and insulin-resistant trajectories, and integration with biomarkers (e.g., proteomics) to refine risk.
OBJECTIVE: Type 2 diabetes (T2D) and its associated complications develop heterogeneously over decades, but few studies span the progression from prediabetes to clinical events. We investigated whether long-term metabolic trajectories beginning in prediabetes delineate subgroups with differential complication risk. RESEARCH DESIGN AND METHODS: Clinical data from 1,732 Diabetes Prevention Program/Outcomes Study participants (follow-up 19 years) were analyzed across 12 phenotypes. Tensor decomposition was used to capture longitudinal patterns, and Gaussian mixture modeling was used to define longitudinal clusters. Cluster-specific complications were quantified with Cox and logistic regression. RESULTS: Four clusters emerged. Clusters 1 and 2 (73% of participants) maintained stable glycemia, blood pressure, and lipids. Although 49% and 71%, respectively, developed T2D, cumulative micro- and macrovascular events remained low. Cluster 3 (12%) showed the steepest rise in insulin resistance and hyperglycemia, with 92% of the subgroup progressing to T2D and a markedly higher rate of retinopathy (odds ratio [OR] 8.8, 95% CI 3.9-20.1) and neuropathy (OR 3.4, 95% CI 2.1-5.5). Cluster 4 (15%) presented with baseline microalbuminuria often prior to the development of T2D (73%). It was distinguished by progressive estimated glomerular filtration rate decline and a doubling of cardiovascular events (hazard ratio 2.0, 95% CI 1.4-3.0), despite serum lipids comparable with other groups. CONCLUSIONS: Two-thirds of individuals with prediabetes follow metabolically resilient trajectories, whereas distinct insulin-resistant or renal-dysfunction trajectories precede micro- or macrovascular complications, respectively. The optimal window for macrovascular complication prevention in individuals with prediabetes microalbuminuria may precede progression to T2D.